Slingshot Insights | Nvo Overview

NVO Overview

Upcoming Projects (NVO)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (NVO)

Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 24, 2024 at 04:56 PM EDT
Investigating the potential of liraglutide, a GLP-1 agonist from Novo Nordisk as a preventative treatment of Alzheimer's disease.
Ticker: NVO
Executed On: Oct 01, 2024 at 04:00 PM EDT
Discussing the potential of INV-202 (Monlunabant), a CB1 antagonist currently in development by Novo Nordisk for weight loss
Tickers: NVO, LLY, CRBP
Executed On: Aug 20, 2024 at 10:30 AM EDT
Digging into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Tickers: LLY, NVO
Executed On: Aug 14, 2024 at 01:00 PM EDT
Discussing the SURMOUNT-OSA phase 3 clinical trial of tirzepatide in patients with obstructive sleep apnea and obesity
Tickers: LLY, NVO
Executed On: Aug 06, 2024 at 10:00 AM EDT
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic July 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Aug 01, 2024 at 10:42 AM EDT
Looking at the impact of GLP-1 weight loss medications on the Continuous Glucose Monitoring (CGM) Market in Type 2 Diabetes
Tickers: DXCM, SENS, ABT, MDT, LLY, NVO
Executed On: Jul 30, 2024 at 12:00 PM EDT
Exploring the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy for obesity and type 2 diabetes
Tickers: GUTS, NVO, LLY
Executed On: Jul 19, 2024 at 02:30 PM EDT
A Second Opinion: Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide
Tickers: ZEAL, NVO, LLY
Executed On: Jul 09, 2024 at 04:30 PM EDT
Looking at the potential of long-acting amylin analogs for weight management, with a close look at the phase 1b data on Zealand Pharmaceuticals Petrelintide
Tickers: ZEAL, NVO, LLY
Executed On: Jun 27, 2024 at 10:30 AM EDT
A Second Opinion: Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 14, 2024 at 11:00 AM EDT
Discussing Structure's recent 12-week topline obesity data from its Phase 2a study of GSBR-1290 & topline results from its capsule to tablet PK study patients with obesity
Tickers: GPCR, NVO, LLY
Executed On: Jun 13, 2024 at 02:40 PM EDT
Discussing the recent data from the FLOW trial and the effects of Novo Nordisk's semaglutide on chronic kidney disease in patients with type 2 diabetes.
Ticker: NVO
Executed On: Jun 06, 2024 at 11:00 AM EDT
Discussing the landscape of Novo Nordisk's (NVO) Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults with Type 2 diabetes
Ticker: NVO
Executed On: May 24, 2024 at 10:00 AM EDT
Discussing the CB1 axis to treat obesity, including CBR-913 and nimicimab
Tickers: CRBP, SKYE, NVO
Executed On: May 06, 2024 at 03:00 PM EDT
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic April 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Apr 18, 2024 at 03:17 PM EDT
A look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Tickers: NVO, LLY
Executed On: Mar 22, 2024 at 09:30 AM EDT
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jan 22, 2024 at 01:24 PM EST
Discussing the impact of GLP-1 agonists on patient eligibility for bariatric surgeries and the need for new surgical systems
Tickers: ISRG, NVO, LLY, MDT
Executed On: Dec 08, 2023 at 01:15 PM EST
A Payor Perspective: Discussing reimbursement for GLP-1 drugs based on cardiovascular benefits with a focus on the SELECT trial
Tickers: NVO, LLY
Executed On: Dec 06, 2023 at 02:00 PM EST
Discussing the potential of semaglutide in chronic kidney disease and Novo Nordisk's recent decision to stop the kidney outcomes trial, FLOW based on interim analysis
Ticker: NVO
Executed On: Nov 15, 2023 at 04:30 PM EST
Quarterly Survey: Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 26, 2023 at 04:59 PM EDT
A Third Perspective: Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results
Tickers: AKRO, ENTB, MDGL, LLY, NVO
Executed On: Oct 20, 2023 at 03:45 PM EDT
A Second Perspective: Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results
Tickers: AKRO, ENTB, MDGL, LLY, NVO
Executed On: Oct 16, 2023 at 01:00 PM EDT
Discussing the NASH landscape in the aftermath of the Akero's efruxifermin results
Tickers: AKRO, ENTB, MDGL, LLY, NVO
Executed On: Oct 13, 2023 at 12:00 PM EDT
A Second Look: Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with an endocrinologist
Tickers: NVO, LLY
Executed On: Sep 13, 2023 at 11:00 AM EDT
A Second Look: Discussing the potential of Allurion Technologies weight loss balloon for obesity management
Tickers: ALUR, NVO, LLY
Executed On: Aug 28, 2023 at 03:00 PM EDT
Discussing the SELECT trial and WEGOVY's (semaglutide) potential to reduce the risk of major adverse cardiovascular events (MACE) with a cardiologist
Tickers: NVO, LLY, AZN
Executed On: Aug 22, 2023 at 02:15 PM EDT
Discussing the potential of Allurion Technologies weight loss balloon for obesity management
Tickers: ALUR, NVO, LLY
Executed On: Aug 11, 2023 at 10:30 AM EDT
Quarterly Survey: Diabetes GLP-1 Treatments and LLY's Mounjaro and NVO's Ozempic July 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jul 25, 2023 at 05:46 PM EDT
Discussing private and commercial payor reimbursement strategies in the US for obesity drugs such as semaglutide and tirzepatide
Tickers: NVO, LLY
Executed On: Jul 20, 2023 at 11:00 AM EDT
Quarterly Survey: Diabetes GLP-1 Treatments and Mounjaro tirzepatide April 2023
Tickers: LLY, NVO, AZN
Executed On: Apr 12, 2023 at 02:43 PM EDT
Checking in with a prescriber of Novartis' Rybelsus (semaglutide) as a first-line therapy for adults with type 2 diabetes.
Ticker: NVO
Executed On: Jan 23, 2023 at 04:30 PM EST
Digging into the clinical landscape of Type 2 Diabetes and the potential of Novo Nordisk's once weekly insulin Icodec
Ticker: NVO
Executed On: Nov 02, 2022 at 12:00 PM EDT
A Second Opinion: Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, NVO, MDGL
Executed On: Aug 01, 2022 at 12:00 PM EDT
Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, MDGL, NVO
Executed On: Jul 13, 2022 at 03:00 PM EDT
A look at tirzepatide's Phase 3 data in Type 2 Diabetes and Obesity in comparison with semaglutide and other GLP-1's, and examining the potential market opportunity for tirzepatide in Type 2 Diabetes and Obesity
Tickers: LLY, NVO
Executed On: May 05, 2022 at 03:00 PM EDT
A look at the pending PDUFA of tirzepatide and how it may compare to Rybelsus (semaglutide) and the Type 2 diabetes space as a whole
Tickers: LLY, NVO
Executed On: Apr 21, 2022 at 04:00 PM EDT

Expired Projects (NVO)

Discussing the Landscape of the Injectable Long-Acting Insulin Market for Merck's Glargine (MK-1293) in Type 1 & 2 Diabetes Following Expected April PDUFA
Tickers: MRK, SNY, LLY, NVO
Execute By: Apr 14, 2017
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
Understanding the potential of Novo Nordisk's (NVO) Tresiba in treatment of type 2 diabetes
Ticker: NVO
Execute By: Feb 05, 2016

Upcoming & Overdue Catalysts (NVO)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (NVO)

PDUFA for Novo Nordisk's (NVO) N8-GP in Hemophilia A expected February 26, 2019.
Ticker: NVO
Occurred on: Feb 19, 2019
Post hoc subgroup analyses released of the Phase 3 MACE and SUSTAIN 6 studies evaluating Novo Nordisk's (NVO) OZEMPIC (semaglutide) in type 2 diabetics with high CV risk
Ticker: NVO
Occurred on: Aug 26, 2018
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017
CHMP Recommends Addition of SWITCH 1 and SWITCH 2 Data to Novo's (NVO) Tresiba
Ticker: NVO
Occurred on: Mar 24, 2017
CHMP Recommends Novo's (NVO) Refixia for Approval in Hemophilia B
Ticker: NVO
Occurred on: Mar 24, 2017
European Commission Approves Novo's (NVO) Fast Acting Insulin Fiasp
Ticker: NVO
Occurred on: Jan 10, 2017
Novo Nordisk expects to file semaglutide for regulatory review in the US and EU in the fourth quarter of 2016
Ticker: NVO
Occurred on: Dec 05, 2016
Novo Nordisk (NVO) receives US FDA approval for Xultophy 100/3.6
Ticker: NVO
Occurred on: Nov 21, 2016
Novo Nordisk's (NVO) Fiasp (Fast-Acting Insulin Aspart) in Type 1 and Type 2 Diabetes Granted Positive Opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)
Ticker: NVO
Occurred on: Nov 14, 2016
Novartis's (NVO) Midostaurin (PKC412) Granted Priority Review by FDA for Acute Myeloid Leukemia (AML) and Mastocytosis
Ticker: NVO
Occurred on: Nov 14, 2016
Novo Nordisk (NVO) Submits Type 2 Variation Application to EMA to Add Data from Two Late-Stage Studies to Label for Long-Acting Diabetes Med Tresiba
Ticker: NVO
Occurred on: Nov 10, 2016
Novo Nordisk's (NVO) NDA for Faster-Acting Insulin Rejected by FDA
Ticker: NVO
Occurred on: Oct 11, 2016
Novo Nordisk submits application in the US for including data from the two SWITCH trials in Tresiba label
Ticker: NVO
Occurred on: Sep 23, 2016
IDegLira receives positive 16-0 vote in favour of approval from FDA Advisory Committee
Ticker: NVO
Occurred on: May 24, 2016
Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial
Ticker: NVO
Occurred on: Apr 28, 2016
Victoza significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
Ticker: NVO
Occurred on: Mar 04, 2016
Novo Nordisk (NVO) Expects to Release Data from SWITCH-1 Trial Evaluating Tresiba in Type 1 Diabetes Patients in Q1 2016
Ticker: NVO
Occurred on: Feb 23, 2016
Tresiba demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes
Ticker: NVO
Occurred on: Feb 23, 2016
Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes
Ticker: NVO
Occurred on: Feb 23, 2016
Tresiba demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes; headline results of SWITCH 1 expected later in the first quarter of 2016
Ticker: NVO
Occurred on: Jan 29, 2016
Top-line Phase 3b Data Released From Novo Nordisk's (NVO) SWITCH-2 Trial Evaluating Tresiba Versus Insulin Glargine in Type 2 Diabetes Patients
Ticker: NVO
Occurred on: Jan 29, 2016

Strategic Initiatives (NVO)

Novo Nordisk (NVO) Submits Supplemental New Drug Application in U.S and Canada to Include the Cardiovascular Outcomes on Labels From LEADER Study for Victoza in Type 2 diabetes
Ticker: NVO
Announcement Date: Oct 26, 2016